SCHEMBL773932

SCHEMBL773932

CN(C)C=C(C(=O)O)C(=O)c1ccncc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.49
NAPRT Q6XQN6 1/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 4/20 0.41
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 5/20 0.38
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HSD17B10 Q99714 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
PLOD2 O00469 1/20 0.37
PLOD3 O60568 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
PLOD1 Q02809 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773931 1.00 HTT (0.49) HTTNAPRTKMT2AKDM4ELMNA
SCHEMBL7380616 0.86 HTT (0.49) HTTNAPRTKMT2AKDM4ELMNA
SCHEMBL10808087 0.86 HTT (0.49) HTTNAPRTKMT2AKDM4ELMNA
SCHEMBL4291907 0.84 RAB9A (0.48) KMT2AKDM4ELMNAMEN1ALDH1A1
SCHEMBL4291901 0.84 RAB9A (0.48) KMT2AKDM4ELMNAMEN1ALDH1A1
SCHEMBL20582072 0.79 HCAR2 (0.44) HTTKMT2AKDM4ELMNAMEN1
SCHEMBL20582073 0.79 HCAR2 (0.44) HTTKMT2AKDM4ELMNAMEN1
SCHEMBL6640581 0.79 CYP11B1 (0.56) CYP11B1CYP11B2
SCHEMBL6640583 0.79 CYP11B1 (0.56) CYP11B1CYP11B2
SCHEMBL10938904 0.79 HTT (0.51) HTTNAPRTKMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
EP-2440554-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS Merck Serono S.A. (CH) 2012-04-18 EP disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 HTT 4351/4885NAPRT 2988/4885KMT2A 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.